Careers  |  Media  |  Contact us

OncoLife – Targeted gene panel – Basic- Colorectal

Test Name

OncoLife – Targeted gene panel – Basic- Colorectal

Home Collection, Lab Visit

Test Code

ONCO0034

Test Components/ Genes/ Parameters

KRAS, NRAS, BRAF

Sample Report

Click on Icon

Test Information

TAT DETAILS

14 Days

PRE-TEST INSTRUCTIONS

Submit formalin fixed paraffin embedded Tissue Block. Ship at room temperature

CLINICAL UTILITY

The test detects mutations in KRAS (exons 2, 3, and 4), NRAS (exons 2, 3, and 4) and BRAF (codon 600 in exon 15) genes, all being part of the EGFR signaling cascade, are mutated in approximately 45–55% of the mCRC cases. Patients whose tumours have a mutated RAS gene are unlikely to respond to treatment with anti-epidermal growth factor receptor therapy such as cetuximab and panitumumab. Patients with metastatic disease with wild-type (normal) RAS genes are likely to respond to these treatments, which improve the overall response to chemotherapy.

SPECIMEN STABILITY

Transport at ambient (18-25°C) temperature

METHODOLOGY

NGS

STORAGE TEMPERATURE

NA

SPECIMEN TYPE

Surgical tissue/Tissue Block

Frequently Asked Questions

OncoLife – Targeted gene panel – Basic- Colorectal
To determine whether a cancer, usually a large bowel (colorectal) cancer is positive for KRAS, NRAS or BRAF gene mutation, which helps to guide treatment and determine outcome. RAS gene mutation analysis is also used in the assessment of some other cancer types including head and neck cancer
The patient should carry the FFPE tissue or block of the Colon. This process is carried out by Gastero Surgeon in the hospital
If the patient is diagnosed with a Colon cancer and the doctor wants to determine whether the KRAS, NRAS& BRAF genes are mutated in the tumour. If the KRAS, NRAS & BRAF genes are mutated, the cancer will not be responsive to treatment with RAS targetted therapy
The test is performed by NGS technique
There is no risk associated with the test as biopsy will be taken by the trained surgeon in the hospital under anasthesia
The test report comes as mutated or wild type RAS or BRAF gene. Mutated RAS genes are unlikely to respond to treatment with anti-epidermal growth factor receptor therapy such as cetuximab and panitumumab. Patients with metastatic disease with wild-type (normal) RAS genes are likely to respond to these treatments, which improve the overall response to chemotherapy.